Source: International Congress 2018 – Current practices in and attitudes to screening for tuberculosis, and a discussion about genetic diversity
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. Sousa (Paredes, Portugal), A. Ribeiro (Porto, Portugal), Á. Almeida (Porto, Portugal), A. Correia (Porto, Portugal), R. Duarte (Porto, Portugal), C. Carvalho (Porto, Portugal). Cost-effectiveness of two latent tuberculosis infection screening strategies. 3878

Member's Comments

No comment yet.

Related content which might interest you: Direct costs of three models for the screening of latent tuberculosis infection Source: Eur Respir J 2006; 28: Suppl. 50, 343s Year: 2006 Direct costs of three models for the screening of latent tuberculosis infection Source: Eur Respir J 2006; 28: 45-50 Year: 2006 Cost-effectiveness of interferon-γ release assay testing for the treatment of latent tuberculosis Source: Eur Respir J 2007; 30: 321-332 Year: 2007 Diagnosis and treatment of latent tuberculosis infection Source: Eur Respir Monogr 2018; 82: 381-398 Year: 2018 Treatment of latent infection with Mycobacterium tuberculosis: update 2010 Source: Eur Respir J 2011; 37: 690-711 Year: 2011 New guidelines for screening for tuberculosis and latent tuberculosis infection pre-immunosuppressive therapy in the Netherlands: a targeted and stratified approach Source: International Congress 2019 – Tuberculosis: diagnosis and scores Year: 2019 The impact and cost-effectiveness of strategies to detect drug-resistant tuberculosis Source: Eur Respir J 2012; 39: 626-634 Year: 2012 Latent tuberculosis infection in a drug treatment centre Source: Eur Respir J 2002; 20: Suppl. 38, 366s Year: 2002 Experience in the use of Bedakville in the therapy of multidrug-resistant tuberculosis and HIV infection. Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018 Completion of treatment for latent tuberculosis infection Source: Annual Congress 2011 - Clinical tuberculosis Year: 2011 Benefit of treatment of latent tuberculosis infection in individual patients Source: Eur Respir J 2016; 47:1594-1595 Year: 2016 Benefit of treatment of latent tuberculosis infection in individual patients Source: Eur Respir J 2016; 47:1592-1594 Year: 2016 Benefit of treatment of latent tuberculosis infection in individual patients Source: Eur Respir J 2015; 46: 1397-1406 Year: 2015 Advancing global programmatic management of latent tuberculosis infection for at risk populations Source: Eur Respir J 2016; 47:1327-1330 Year: 2016 Diagnosis of latent tuberculosis infection Source: ERS Live 2007 Year: 2007 The use of interferon-γ-based blood tests for the detection of latent tuberculosis infection Source: Eur Respir J 2006; 28: 1-3 Year: 2006 The dynamics of tuberculosis incidence and diagnostics of latent tuberculosis tuberculosis infection in children of Ukraine. Source: International Congress 2018 – Groups who are susceptible to tuberculosis: children, pregnant women and elderly people Year: 2018 Monitoring latent tuberculosis infection diagnosis and management in the Netherlands Source: Eur Respir J 2016; 47:1492-1501 Year: 2016 Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries Source: Eur Respir J 2015; 46: 1563-1576 Year: 2015 Management of latent Mycobacterium tuberculosis infection: WHO guidelines for countries with a low tuberculosis burden Source: International Congress 2016 – ERS publications: a focus on recent guidelines and task forces Year: 2016